(Q44371425)

2 December 2017

title

Type IV phosphodiesterase inhibition improves cardiac contractility in endotoxemic rats (English)

1 reference

2 December 2017

Neal J Thomas

1

1 reference

2 December 2017

Joseph A Carcillo

2

1 reference

2 December 2017

William A Herzer

3

1 reference

2 December 2017

Zaichuan Mi

4

1 reference

2 December 2017

Stevan P Tofovic

5

1 reference

2 December 2017

Edwin K Jackson

6

1 reference

2 December 2017

language of work or name

English

0 references

publication date

1 March 2003

1 reference

European Journal of Pharmacology

2 December 2017

published in

1 reference

2 December 2017

volume

465

1 reference

2 December 2017

issue

1-2

1 reference

2 December 2017

page(s)

133-139

1 reference

Rolipram, a specific type IV phosphodiesterase inhibitor, is a potent inhibitor of HIV-1 replication.

2 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901456-0

Formation of reactive oxygen metabolites in glomeruli is suppressed by inhibition of cAMP phosphodiesterase isozyme type IV

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901456-0

Phosphodiesterase type IV inhibitors in the treatment of multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901456-0

Cyclic-3',5'-nucleotide phosphodiesterase isozymes in cell biology and pathophysiology of the kidney

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901456-0

Protection by phosphodiesterase inhibitors against endotoxin-induced liver injury in galactosamine-sensitized mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901456-0

Isoenzyme selective phosphodiesterase inhibitors: potential clinical uses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901456-0

Effects of type IV phosphodiesterase inhibition on cardiac function in the presence and absence of catecholamines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901456-0

Phosphodiesterases in the rat renal vasculature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901456-0

The adenylate cyclase-cAMP-protein kinase A pathway and regulation of the immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901456-0

Anti-inflammatory effects of the novel phosphodiesterase IV inhibitor RP 73401

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901456-0

Cardiotonic actions of selective phosphodiesterase inhibitors in rat isolated ventricular cardiomyocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901456-0

Characterisation of cyclic nucleotide phosphodiesterases from rat mesenteric artery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901456-0

Modulation of TNF alpha and IL-1 beta from endotoxin-stimulated monocytes by selective PDE isozyme inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901456-0

The role of cAMP regulation in controlling inflammation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901456-0

Involvement of Rolipram-Sensitive Cyclic AMP Phosphodiesterase in the Regulation of Cardiac Contraction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901456-0

Inhibitors of cyclic nucleotide phosphodiesterases as therapeutic agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901456-0

Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901456-0

Inotropic Responses to Selective (RO 20–1724 and SQ 65, 442) and Nonselective (Trequinsin) Inhibitors of Cyclic AMP-Specific Class IV Phosphodiesterase in Newborn, Immature, and Adult Rabbit Myocardium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901456-0

Characterization of cAMP-dependent inhibition of LPS-induced TNF alpha production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901456-0

The specific type III and IV phosphodiesterase inhibitor zardaverine suppresses formation of tumor necrosis factor by macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901456-0

PDE isoenzymes as targets for anti-asthma drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901456-0

Anti-inflammatory activity of phosphodiesterase (PDE)-IV inhibitors in acute and chronic models of inflammation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901456-0

The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-alpha production by human mononuclear cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901456-0

Comparison of cyclic nucleotide phosphodiesterase isoenzymes in rat and rabbit ventricular myocardium: positive inotropic and phosphodiesterase inhibitory effects of Org 30029, milrinone and rolipram

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901456-0

Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNF alpha generation from human monocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901456-0

Identification and characterization of isoenzymes of cyclic nucleotide phosphodiesterase in human kidney and heart, and the effects of new cardiotonic agents on these isoenzymes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901456-0

Mechanism of preserved positive lusitropy by cAMP-dependent drugs in heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901456-0

Cyclic nucleotide phosphodiesterases: pharmacology, biochemistry and function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901456-0

Inhibition of cytokine release by and cardiac effects of type IV phosphodiesterase inhibition in early, profound endotoxaemia in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901456-0

Subclasses of cyclic AMP-specific phosphodiesterase in left ventricular muscle and their involvement in regulating myocardial contractility

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901456-0

Effect of milrinone on left ventricular relaxation and Ca(2+) uptake function of cardiac sarcoplasmic reticulum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901456-0

10.1016/S0014-2999(03)01456-0

7 January 2021

Identifiers

DOI

1 reference

2 December 2017

1 reference